Sunny Pharmtech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	290.18	418.01	428.83	359.59	241	419.94
Revenue Growth (YoY)	-40.17%	-2.52%	19.26%	49.21%	-42.61%	79.09%
Cost of Revenue	134.7	191.61	143.3	152.88	125.25	195.87
Gross Profit	155.48	226.4	285.53	206.71	115.75	224.07
Selling, General & Admin	178.35	170.11	148.76	138.45	120.39	116.37
Research & Development	231.14	219.28	208.87	255.88	171.37	182.04
Operating Expenses	409.49	389.39	357.62	394.33	291.75	298.41
Operating Income	-254.01	-162.99	-72.1	-187.62	-176	-74.34
Interest Expense	-9.74	-9.07	-11.24	-4.59	-5.62	-6.8
Interest & Investment Income	3.37	4.54	5.73	1.38	0.36	1.48
Currency Exchange Gain (Loss)	-9.56	10.74	12.23	16.15	-3.18	-26.69
Other Non Operating Income (Expenses)	0.42	0.7	3.38	4.53	3.31	2.88
EBT Excluding Unusual Items	-269.51	-156.08	-62	-170.15	-181.14	-103.46
Gain (Loss) on Sale of Assets	-	0.08	-0.08	-0.09	-	-
Asset Writedown	-	-	-1.24	-	-	-6.18
Other Unusual Items	-	-	-	-	4.48	7.89
Pretax Income	-269.51	-156	-63.32	-170.24	-174.79	-101.76
Earnings From Continuing Operations	-269.51	-156	-63.32	-170.24	-174.79	-101.76
Net Income	-269.51	-156	-63.32	-170.24	-174.79	-101.76
Net Income to Common	-269.51	-156	-63.32	-170.24	-174.79	-101.76
Shares Outstanding (Basic)	149	149	143	139	134	129
Shares Outstanding (Diluted)	149	149	143	139	134	129
Shares Change (YoY)	0.66%	4.20%	3.04%	3.60%	3.29%	2.70%
EPS (Basic)	-1.81	-1.05	-0.44	-1.23	-1.31	-0.79
EPS (Diluted)	-1.82	-1.05	-0.44	-1.23	-1.31	-0.79
Free Cash Flow	-145.81	-82.81	-105.88	-152.3	-193.31	-91.04
Free Cash Flow Per Share	-0.98	-0.56	-0.74	-1.10	-1.45	-0.70
Gross Margin	53.58%	54.16%	66.58%	57.48%	48.03%	53.36%
Operating Margin	-87.53%	-38.99%	-16.81%	-52.18%	-73.03%	-17.70%
Profit Margin	-92.88%	-37.32%	-14.77%	-47.34%	-72.53%	-24.23%
Free Cash Flow Margin	-50.25%	-19.81%	-24.69%	-42.35%	-80.21%	-21.68%
EBITDA	-137.79	-48.45	41.34	-83.09	-76.24	26.9
EBITDA Margin	-47.48%	-11.59%	9.64%	-23.11%	-31.64%	6.40%
D&A For EBITDA	116.22	114.54	113.44	104.53	99.76	101.24
EBIT	-254.01	-162.99	-72.1	-187.62	-176	-74.34
EBIT Margin	-87.53%	-38.99%	-16.81%	-52.18%	-73.03%	-17.70%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.